London, UK (PRWEB) March 05, 2015
The emergence of nanotechnology has greatly impacted the clinical therapeutics landscape over the past decade. The pharmaceutical world has witnessed advancements in biocompatible nanoscale carriers for drug delivery in the form of liposomes and polymeric nanoparticles that are capable of delivering manifold drugs with more safety and efficiency. In the area of cancer therapeutics, the nanoparticles could perhaps rely greatly upon the enhanced permeability and retention (EPR) effect induced by leaky tumour vasculatures for a better accumulation of drugs at the tumour sites. Due to these benefits, the therapeutic nanoparticles in this respect have grown into a very promising field with the potential to successfully take the place of traditional chemotherapy.
The development of nanoparticle drug delivery systems for the treatment of cancer is set to become a lucrative field in the years to come. The protein polymers from natural sources emerge as up-and-coming materials for building the nanocarrier systems. The commercial success of albumin-based nanoparticles has also generated great interest in other proteins. With the rational design of protein nanoparticles on the grounds of their behaviours in the tumour microenvironment and based on the cell biology of cancer, enhanced cancer treatment efficacy and safety can be achieved.
Topical report “Cancer Nanomedicine Market & Pipeline Insight 2015” worked out by Kuick Research is now available at MarketPublishers.com.
Title: Cancer Nanomedicine Market & Pipeline Insight 2015
Published: February, 2015
Price: US$ 2,000.00
The report offers an essential guide to the worldwide cancer nanomedicine marketplace. It provides deep insights into the role of nanomedicine in cancer therapies, contains a detailed classification of cancer nanoparticles drug delivery systems, looks at the mechanism of tumour nanomedicine treatment. The study presents a deep overview of the cancer nanomedicine clinical development pipeline, looking at it based on indication, stage and company. It reviews the 79 candidates in clinical development, the 8 marketed cancer nanomedicine drugs. The competitive landscape is canvassed as well including a discussion of the 11 leading companies. The report casts light on the market dynamics covering key drivers and commercialisation challenges, besides speculating on the future prospects of the market.
Companies reviewed comprise: Abraxis BioScience, Alnylam Pharmaceuticals, Access Pharmaceuticals, Bind Biosciences, Samyang, Arrowhead Research, Epeius Biotechnologies, Nanobiotix, Nippon Kayaku, NanoCarrier, and Takeda Pharmaceutical.
- Comprehensive look at nanomedicine in cancer therapies as well as mechanisms.
- In-depth analysis of the world market for cancer nanomedicines.
- Examination of the market dynamics, including key growth propellers, challenges and future projections.
- All-round discussion of the cancer nanomedicine pipeline by phase, indication, and company.
- Review and examination of the 79 cancer nanomedicines currently in development stage.
- Identification and detailed analysis of the 8 marketed drugs.
- All-round analysis of the competitive scene and the 11 major players.
More topical studies by the publisher can be found at Kuick Research page.